<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Serine protease granzyme B plays important roles in <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, <z:hpo ids='HP_0002960'>autoimmunity</z:hpo>, transplant rejection, and antitumor immunity </plain></SENT>
<SENT sid="1" pm="."><plain>A triple-mutated granzyme B variant that encodes three amino substitutions (Q48R, P88A, and Y245H) has been reported to have altered biological functions </plain></SENT>
<SENT sid="2" pm="."><plain>In the polymorphism rs8192917 (2364A&gt;G), the A and G alleles represent <z:mp ids='MP_0002169'>wild type</z:mp> QPY and RAH mutant variants, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we analyzed the impact of granzyme B polymorphisms on transplant outcomes in recipients undergoing unrelated HLA-fully matched T-cell-replete bone marrow transplantation (BMT) through the Japan Donor Marrow Program </plain></SENT>
<SENT sid="4" pm="."><plain>The granzyme B genotypes were retrospectively analyzed in a cohort of 613 pairs of recipients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and their unrelated donors </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> consisting of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, the donor G/G or A/G genotype was associated with improved overall survival (OS; adjusted hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41-0.89; P = 0.01) as well as transplant related mortality (TRM; adjusted HR, 0.48; 95% CI, 0.27-0.86, P = 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>The recipient G/G or A/G genotype was associated with a better OS (adjusted HR, 0.68; 95% CI, 0.47-0.99; P = 0.05) and a trend toward a reduced TRM (adjusted HR, 0.61; 95% CI, 0.35-1.06; P = 0.08) </plain></SENT>
<SENT sid="7" pm="."><plain>Granzyme B polymorphism did not have any effect on the transplant outcomes in patients with lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> consisting of <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> and malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that there is an association between the granzyme B genotype and better clinical outcomes in patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> after unrelated BMT </plain></SENT>
</text></document>